Eslit, Marivit P.

HRN: 26-76-63  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/12/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/12/2025
05/18/2025
IVTT
2.25 G
Q6
Sepsis
Waiting Final Action 
05/13/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
05/13/2025
05/20/2025
IV
4.5 Gram
Q6h
Infected Breast Mass
Waiting Final Action 
05/13/2025
CLINDAMYCIN 300MG (CAP)
05/13/2025
05/20/2025
PO
300 Mg
Q6h
Infected Breast Mass
Waiting Final Action 
05/13/2025
MUPIROCIN 2%, 15G (TUBE)
05/13/2025
05/20/2025
TOPICAL
1 Gram
Q8h
Infected Breast Wound
Waiting Final Action 
05/13/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
05/13/2025
05/20/2025
IV
2.5 Gram
Q6h
CAP MR; Infected Breast Mass
Waiting Final Action 
05/14/2025
AZITHROMYCIN 500MG TABLET (TAB)
05/14/2025
05/21/2025
PO
500 Mg
OD
CAP MR
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: